AU2001268303A1 - Hepatitis c protease exosite for inhibitor design - Google Patents

Hepatitis c protease exosite for inhibitor design

Info

Publication number
AU2001268303A1
AU2001268303A1 AU2001268303A AU6830301A AU2001268303A1 AU 2001268303 A1 AU2001268303 A1 AU 2001268303A1 AU 2001268303 A AU2001268303 A AU 2001268303A AU 6830301 A AU6830301 A AU 6830301A AU 2001268303 A1 AU2001268303 A1 AU 2001268303A1
Authority
AU
Australia
Prior art keywords
exosite
hepatitis
protease
inhibitor design
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001268303A
Inventor
Mark S. Hixon
Charles A. Kettner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of AU2001268303A1 publication Critical patent/AU2001268303A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
AU2001268303A 2000-06-11 2001-06-08 Hepatitis c protease exosite for inhibitor design Abandoned AU2001268303A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21090000P 2000-06-11 2000-06-11
US60/210,900 2000-06-11
PCT/US2001/018751 WO2001096540A2 (en) 2000-06-11 2001-06-08 Hepatitis c protease exosite for inhibitor design

Publications (1)

Publication Number Publication Date
AU2001268303A1 true AU2001268303A1 (en) 2001-12-24

Family

ID=22784757

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001268303A Abandoned AU2001268303A1 (en) 2000-06-11 2001-06-08 Hepatitis c protease exosite for inhibitor design

Country Status (3)

Country Link
US (1) US20020102533A1 (en)
AU (1) AU2001268303A1 (en)
WO (1) WO2001096540A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
PL2298766T3 (en) 2005-03-03 2014-09-30 H Lundbeck As Pharmaceutical formulations comrpising a substituted pyridine derivative
US10590067B2 (en) 2018-02-20 2020-03-17 H. Lundbeck A/S Alcohol derivatives of carboxamides as Kv7 potassium channel openers
MD3755684T2 (en) 2018-02-20 2023-11-30 H Lundbeck As Alcohol derivatives as Kv7 potassium channel openers
AR119521A1 (en) 2019-08-02 2021-12-22 H Lundbeck As ALCOHOL DERIVATIVES AS Kv7 POTASSIUM CHANNEL OPENERS
WO2021023616A1 (en) 2019-08-02 2021-02-11 H. Lundbeck A/S Alcohol derivatives as kv7 potassium channel openers for use in epilepsy or seizures
JOP20220017A1 (en) 2019-08-02 2023-01-30 H Lundbeck As Alcohol derivatives as kv7 potassium channel openers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE911130A1 (en) * 1990-04-04 1991-10-09 Protos Hepatitis c protease inhibitors

Also Published As

Publication number Publication date
WO2001096540A2 (en) 2001-12-20
WO2001096540A3 (en) 2003-03-06
US20020102533A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
AU2001269836A1 (en) Proteases
AU2001271427A1 (en) Novel proteases
AU2001249395A1 (en) Isolated instructions for isolated execution
IL150964A0 (en) Protease inhibitors
AU2108601A (en) Salicylamides as serine protease inhibitors
AU2001285750A1 (en) Urokinase inhibitors
AU2001247589A1 (en) Non-amidine containing protease inhibitors
AU2001270792A1 (en) Surfactant
IL153421A0 (en) Protease inhibitors
AU2001268303A1 (en) Hepatitis c protease exosite for inhibitor design
AU1588901A (en) Protease inhibitors
AU2001247483A1 (en) Proteases
IL151087A0 (en) Protease inhibitors
AU1474801A (en) Protease inhibitors
AU1474701A (en) Protease inhibitors
AU1474601A (en) Protease inhibitors
AU4066900A (en) Protease inhibitors
AU2001292594A1 (en) Proteases
HUP0301964A3 (en) Protease inhibitors
AU2001259565A1 (en) Proteases
IL155573A0 (en) Novel compounds for use as hiv protease inhibitors
AU5709500A (en) Serine protease inhibitor
AU2001234146A1 (en) Method for inhibiting trypsin-type serine proteases
AU2001244658A1 (en) Gamma-secretase-like protease inhibitors
AU2001263003A1 (en) Carboxyalkylether-acat inhibitor combinations